Auditing AI prior authorization: a provider-side verification framework for specialty clinics
If your team already drafts prior authorizations with AI, the question is whether you can defend each one. A four-layer framework: citation grounding, payer-policy grounding, code cross-validation, and resubmission lineage.
If your billing team already uses AI to draft prior authorizations, the open question is no longer whether to automate. It is whether you can defend each submission, field by field, to a payer reviewer, a RAC auditor, or your own compliance lead. This is a vendor-neutral framework for doing that. It runs against whatever AI prior-auth tool you use, including one your engineers built.
Three things converged in early 2026 to make this urgent.
CMS-0057-F took effect on January 1, 2026. Impacted payers (Medicare Advantage, Medicaid and CHIP) must decide expedited prior authorizations within 72 hours and standard ones within seven calendar days, and since March 31, 2026 they publish approval, denial, and appeal-overturn rates on their public sites. Providers now have benchmarks to defend against.
Insurer-side AI in utilization review is under more scrutiny than at any point since the first PA-AI lawsuits. State rules are following: California now requires insurers running utilization review to test their AI tools for accuracy on a regular cadence. The same expectations are flowing to providers through vendor reviews and compliance teams.
And provider-side AI is now common. The conversation has flipped from should we automate prior auth to how do we trust the automation we already run. Almost none of the published guidance answers that. Most of what ranks for AI prior authorization is either a vendor page selling AI to a health plan or journalism about insurer-side harm. This fills the operator gap.
What audit means here
Audit is not only retrospective. A working framework covers three moments, and most AI prior-auth tools handle only the first.
Pre-submission verification: before the request leaves your portal or clearinghouse, can you defend each field? Is the clinical claim grounded in the chart? Is the payer-rule claim grounded in the payer's current policy? Do the codes match the note?
Submission lineage: when a request is denied and resubmitted, can you reconstruct what changed across attempts and why? If your tool overwrites the prior attempt, or treats every resubmit as a fresh request with no link back, you have a gap.
Outcome defense: when a payer, auditor, or regulator asks for proof, can you produce the source citation and the human-review record behind each AI-generated field? Without that, the AI's output behaves like rumor, not evidence.
The four-layer verification framework
- 01Citation groundingEach clinical claim resolves to a specific chart record (an encounter note, lab, or medication entry) with its date, not a paraphrase the model wrote.
- 02Payer-policy groundingEach payer-rule claim cites the current policy section with a retrieval timestamp. Policies move often, so a six-month-old snapshot can already be wrong.
- 03Code cross-validationICD-10, CPT, HCPCS, and NDC codes are checked against the narrative note. A code that contradicts the documentation is flagged for clinician review before submission.
- 04Resubmission lineageA denied-then-resubmitted request links back to the original with a field-level diff and a reason code for each change. This is the layer most tools skip.
Run citation grounding in supervised mode for high-cost specialty work: a clinician reviews the citations before the request goes out. Reserve autonomous mode for routine, low-stakes preparation. A denied or audit-challenged biologic, infusion, or Spravato request costs far more than a few minutes of review.
What each layer catches
Citation grounding catches the paraphrase failure: an AI sentence that sounds right but points to no record, or to a record that says something else. That is the same failure mode raised in the insurer-side AI cases, and it shows up on the provider side too.
Payer-policy grounding catches stale-policy risk. UnitedHealthcare, Cigna, Aetna, and the major Blue Cross Blue Shield plans update specialty-drug policy often. Grounding against a cached snapshot quietly drifts out of date until a denial pattern forces you to notice.
It also catches the multi-PBM mismatch. A self-funded plan can carry one pharmacy benefit manager for the medical benefit and another for pharmacy. Eligibility may return one and miss the other, so the request gets grounded against the wrong policy.
Code cross-validation catches the copy-paste template error that surfaces months later as an upcoding question. The submission record should show the codes were checked against the note, with either a clean match or a clinician-acknowledged override.
Questions to ask your AI prior-auth vendor
Run this list during evaluation, or against the tool you already use.
- For each AI-drafted clinical claim in a sample request, can you show the exact chart record behind it?
- For each payer-rule claim, can you show the live policy section and the retrieval timestamp?
- Is there a supervised mode where a clinician reviews citations before submission, configurable by drug class or procedure?
- When a request is denied and resubmitted, does the record link back to the original with field-level diffs and a reason per change?
- Are codes cross-validated against the clinical note before submission?
- Are citation thresholds configurable, so a high-cost drug can require stricter grounding than a routine study?
- When an auditor asks for the trail on one request, what artifact does the system produce, and how fast?
A vendor that answers all seven cleanly is rare. A vendor that cannot answer four of them should not run your specialty-drug volume on autopilot.
Specialty notes
Behavioral health (Spravato, TMS): REMS attestations and step-therapy documentation are where the denials come from. Citation grounding for prior antidepressant trials is the layer that catches the most of them. Our Spravato denial playbook goes deeper here.
GLP-1 weight management: BMI, comorbidity codes, and prior weight-loss attempts dominate the criteria, and the BMI in the chart can drift from the code on the request. See the GLP-1 prior-auth checklist.
Infusion and biologics: high cost, high audit risk. Supervised mode should be the default, and resubmission lineage matters more than usual because peer-to-peer outcomes change documentation mid-cycle.
How Foresight maps to this framework
The framework is vendor-neutral. Here is how Foresight lines up against it, so you can compare your own tool the same way.
- Citation grounding: the ePA service supports a citation-grounded mode where auto-answer responses can be required to cite payer policy and clinical guidelines, with operator-supervised review and configurable confidence thresholds.
- Payer-policy grounding: a pre-submission policy check validates payer-rule claims against synced policy data, with retrieval logged for audit.
- Code cross-validation: structured codes are checked against narrative content extracted from clinical documents, and note-versus-code conflicts are flagged for clinician review before the request leaves.
- Resubmission lineage: a denied request links to its prior attempts through a prior-attempt reference and reason codes, with field-level diffs across the request's life.
- Guardrails: automated-reasoning checks and evidence-span tracking keep generated text tied to its source, and a maybe answer routes to a human rather than a guess.
If your team runs an internal-built workflow, the framework still applies. These features are one implementation, not the only one.
01Does CMS-0057-F require provider-side AI audit?
No. CMS-0057-F applies to impacted payers, not providers. But the same regulatory direction, including California's accuracy-review rule for utilization management, is creating provider-side expectations from compliance and legal teams and from large self-funded employers in vendor reviews.
02Is supervised mode slower than autonomous mode?
Yes, by design. Run supervised on high-cost specialty drugs and procedure-level requests, and autonomous on routine commodity work where a denial is cheap. One denied specialty request costs more than the review time it would have taken.
03We use an EHR with built-in prior-auth features. Do we still need this?
Usually yes. EHR-native tools tend to be strong on clinical citation because they have chart access, but weaker on payer-policy grounding and resubmission lineage. The framework points you to the layers most likely to be thin.
04How often should we audit our own AI prior-auth output?
A monthly spot check is reasonable for most specialty clinics. Pull 5 to 10 random AI-drafted submissions, run them through the four layers, and document any gaps, the same way compliance teams already spot-check human-drafted work.
05What if our vendor cannot show source records for clinical claims?
That signals the AI is paraphrasing rather than retrieving. Paraphrase failures are the same failure mode raised in the insurer-side AI cases, and running that style on autopilot for high-cost requests takes on more audit risk than necessary.
The end-to-end picture
When a payer or auditor asks why you submitted a request the way you did, you should be able to produce, within minutes: each clinical claim with its chart record and date, each payer-rule claim with the policy section and retrieval timestamp, the codes with their cross-validation record, the full resubmission lineage, and the human-review record showing what a clinician approved. Teams that build this now have an easier conversation with payers, auditors, and their own compliance leads. Teams that do not will have a harder one soon.